Cai Jun, Ma Hong, Huang Fang, Zhu Dichao, Zhao Lei, Yang Yudan, Bi Jianping, Zhang Tao
Cancer Center of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022, Hubei, P. R. China; ; Department of Oncology, First Affiliated Hospital of Yangtze University Jingzhou 443000, Hubei, P. R. China.
Cancer Center of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022, Hubei, P. R. China;
Int J Clin Exp Pathol. 2014 Jul 15;7(8):4959-70. eCollection 2014.
Colorectal cancer (CRC) is one of the leading causes of cancer-related death all over the world. Ribosomal s6 kinase4 (RSK4), an X-linked gene, firstly was found as to be a potential tumor suppressive gene in a variety of cancers and is widely participated in signaling pathway. However its role in CRC is unclear. This study is to explore the correlation between the protein expression of RSK4 and clinical pathologic characteristics in colorectal tumors, which might serve as a prognostic determinant of colorectal cancers.
Biopsies of 103 colorectal cancer and 46 matched adjacent noncancerous tissues were collected for analysis of RSK4 protein by immunohistochemistry. The correlation between RSK4 protein expression and the clinical pathological features of colorectal cancers were evaluated by Chi-square test and Fisher's exact test. The survival rates were analyzed by the Kaplan-Meier method, and the relationship between prognostic factors and patient survival was analyzed by the Cox proportional hazard models.
RSK4 was conversely correlated with some pathological classifications (P<0.05 for N, G and clinical staging), and there were no statistically significant differences in age, CEA expression in blood, CA199 and tumors t-staging (x(2) test, P>0.05 for all categories) respectively. Furthermore, patients with high protein level of RSK4 showed prolonged overall survivals (P<0.05). Moreover, multivariate analysis showed that low expression level of RSK is an independent risk factor for high mortality in colorectal cancer.
Low RSK4 expression is correlated with advanced clinical pathologic classifications and is a poor overall survival in colorectal cancer patients. These findings suggest that RSK4 may serve as a useful marker in prognostic evaluation for patients with colorectal cancer.
结直肠癌（CRC）是全球癌症相关死亡的主要原因之一。核糖体S6激酶4（RSK4）是一种X连锁基因，最初被发现是多种癌症中的潜在肿瘤抑制基因，并广泛参与信号通路。然而，其在结直肠癌中的作用尚不清楚。本研究旨在探讨RSK4蛋白表达与结直肠肿瘤临床病理特征之间的相关性，这可能作为结直肠癌的预后决定因素。
收集103例结直肠癌组织及46例配对的癌旁非癌组织活检标本，采用免疫组织化学法分析RSK4蛋白。采用卡方检验和Fisher精确检验评估RSK4蛋白表达与结直肠癌临床病理特征的相关性。采用Kaplan-Meier法分析生存率，采用Cox比例风险模型分析预后因素与患者生存的关系。
RSK4与某些病理分类呈负相关（N、G和临床分期，P<0.05），年龄、血液中CEA表达、CA199和肿瘤t分期差异无统计学意义（χ²检验，所有类别P>0.05）。此外，RSK4蛋白水平高的患者总生存期延长（P<0.05）。此外，多因素分析显示RSK低表达是结直肠癌高死亡率的独立危险因素。
RSK4低表达与晚期临床病理分类相关，是结直肠癌患者总体生存不良的因素。这些发现表明，RSK4可能作为结直肠癌患者预后评估的有用标志物。
